128 related articles for article (PubMed ID: 19943130)
1. MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy.
Gunia S; May M; Koch S; Dietel M; Erbersdobler A
Pathol Oncol Res; 2010 Sep; 16(3):371-5. PubMed ID: 19943130
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD44s in incidental prostate cancer is more strongly associated with Gleason scores on subsequent radical prostatectomies than conventional prognostic parameters.
Gunia S; May M; Koch S; Dietel M; Erbersdobler A
Pathobiology; 2009; 76(6):286-92. PubMed ID: 19955840
[TBL] [Abstract][Full Text] [Related]
3. Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies.
Gunia S; Koch S; May M; Dietel M; Erbersdobler A
Virchows Arch; 2009 May; 454(5):573-9. PubMed ID: 19301031
[TBL] [Abstract][Full Text] [Related]
4. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.
Papadopoulos I; Sivridis E; Giatromanolaki A; Koukourakis MI
Clin Cancer Res; 2001 Jun; 7(6):1533-8. PubMed ID: 11410487
[TBL] [Abstract][Full Text] [Related]
5. [Prostate cancer development after transurethral resection of the prostate--histopathological studies of radical prostatectomy specimens].
Kanno H; Umemoto S; Izumi K; Hasumi H; Osada Y; Ohta J; Mikata K; Tuchiya F
Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):649-59. PubMed ID: 16768146
[TBL] [Abstract][Full Text] [Related]
6. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
7. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
Varghese J; Kuruvilla PM; Mehta N; Rathore RS; Babu M; Bansal D; Pillai B; Sam MP; Krishnamorthy H
Asian Pac J Cancer Prev; 2016; 17(4):2255-8. PubMed ID: 27221926
[TBL] [Abstract][Full Text] [Related]
8. MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.
Eminaga O; Wei W; Hawley SJ; Auman H; Newcomb LF; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave ME; Lin DW; Nelson PS; Thompson IM; True LD; McKenney JK; Feng Z; Fazli L; Brooks JD
PLoS One; 2016; 11(11):e0165236. PubMed ID: 27846218
[TBL] [Abstract][Full Text] [Related]
9. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
10. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
11. Outcome of radical prostatectomy for incidental carcinoma of the prostate.
Melchior S; Hadaschik B; Thüroff S; Thomas C; Gillitzer R; Thüroff J
BJU Int; 2009 Jun; 103(11):1478-81. PubMed ID: 19076134
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients.
Mosli HA; Abdel-Meguid TA; Al-Maghrabi JA; Kamal WK; Saadah HA; Farsi HM
Saudi Med J; 2009 Nov; 30(11):1439-43. PubMed ID: 19882057
[TBL] [Abstract][Full Text] [Related]
14. Nuclear grading versus Gleason grading in small samples containing prostate cancer: a tissue microarray study.
Wittschieber D; Köllermann J; Schlomm T; Sauter G; Erbersdobler A
Pathol Oncol Res; 2010 Dec; 16(4):479-84. PubMed ID: 20414754
[TBL] [Abstract][Full Text] [Related]
15. The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate.
Voges GE; McNeal JE; Redwine EA; Freiha FS; Stamey TA
J Urol; 1992 Mar; 147(3 Pt 2):858-63. PubMed ID: 1371561
[TBL] [Abstract][Full Text] [Related]
16. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
18. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
19. Transurethral resection of the prostate is an independent risk factor for biochemical recurrence after radical prostatectomy for prostate cancer.
Jin K; Qiu S; Liao XY; Zheng XN; Tu X; Tang LS; Yang L; Wei Q
Asian J Androl; 2020; 22(2):217-221. PubMed ID: 31210148
[TBL] [Abstract][Full Text] [Related]
20. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
